Project Grant R01AI186787
Award Date 9/23/25
Completion Date 8/31/30
Dollars Obligated $762K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $453,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, titled "Role of ZNF Proteins in the Establishment and Maintenance of HIV Latency", will support research to evaluate the role of zinc finger (ZNF) proteins in establishing and maintaining HIV-1 reservoirs through...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $824,331 Project Grant to Trustees of Boston College to conduct research on "Understanding Formation and Dynamics of the SIV Reservoir." The research aims to improve understanding of the establishment and persistence of latent viral reservoirs in HIV-infected individuals, particularly the role of naive CD4+ T cells, in...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $244,328 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The award, which began on January 6, 2025 and will be completed by December 31, 2026, supports research on the impact of in utero HIV and antiretroviral exposure on the placenta and birth weight. The study will...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $240,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University to conduct research on characterizing the HIV-1 viral reservoirs that persist even under antiretroviral therapy (ART). The 2-year project aims to identify the cellular sources and genetic diversity of the HIV-1 reservoirs, as well as study the sources and characteristics of the residual viremia...
- This federal Project Grant award for $711,993.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to examine the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 pathogenesis in people living with HIV (PWH). The research aims to assess how MTB disease influences the development of broadly neutralizing HIV-1 antibodies, the emergence of NAb-resistant viral...
- This federal Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $170,411 in funding from August 8, 2025 to July 31, 2030 to support mentorship and training of early career investigators in translational virological research focused on HIV persistence, therapeutic interventions, and drug resistance. The grant recipient, Brigham & Women's Hospital Inc., will leverage...
- This $624,902 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the impact of the HIV accessory protein Vpr on epigenetic remodeling and viral persistence in myeloid cells. The 5-year project, starting on Apr 23, 2025, will focus on characterizing how Vpr induces epigenetic changes to facilitate sustained HIV transcription and latency reactivation, as well as...
- This Project Grant award of $800,389.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The proposed treatment combines soluble IL-15/IL-15RA-FC with a TGF-β pathway blockade and therapeutic vaccination to enhance and restore anti-viral immunity, leading to sustained viral remission...
- This Project Grant award of $463,615.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) will fund a study titled "VIOLA: STUDY OF VIREMIA ON LONG-ACTING ANTIRETROVIRAL THERAPY WITH CABOTEGRAVIR AND RILPIVIRINE" at the University of California, San Francisco. The study aims to assess cabotegravir and rilpivirine concentrations and viral resistance mutations among people with HIV who experience virologic failure...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...